What is claimed:

1. Use of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of migraine in a patient, wherein the medicament is in a form for chronic nightly administration.

2. The use of claim 1, wherein the medicament is to be administered for at least five consecutive nights.

3. The use of claim 1, wherein the medicament is to be administered for at least thirty consecutive nights.

4. The use of claim 1, wherein the medicament is to be administered every other night, for at least ten consecutive nights.

5. The use of claim 1, wherein the medicament is to be administered every other night, for at least thirty consecutive nights.

6. The use of claim 1, wherein the patients' migraines have been refractory to two or more prior monotherapy and/or dual therapy treatment and/or prevention regimens.

7. The use of any one of claims 1 to 6, wherein the medicament is to be administered at a dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, of 25 mg to 200 mg.

8. The use of any one of claims 1 to 6, wherein the medicament is to be administered at a dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, of 25 mg.

9. The use of any one of claims 1 to 6, wherein the medicament is to be administered at a dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-

ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, of 50 mg.

10. The use of any one of claims 1 to 6, wherein the medicament is to be administered at a dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, of 75 mg.

11. The use of any one of claims 1 to 6, wherein the medicament is to be administered at a dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, of 100 mg.

12. The use of any one of claims 1 to 6, wherein the medicament is to be administered at a dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, of 150 mg.

13. The use of any one of claims 1 to 6, wherein the medicament is to be administered at a dose of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, of 200 mg.

14. Use of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of migraine, wherein the medicament is to be administered nightly at an oral dose of 25-200 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof.

15. Use of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of migraine, wherein the medicament is to be administered nightly at an oral dose of 25-200 mg of 2,4,6-trifluoro-N-[6-(1-

methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, for at least five consecutive nights.

16. Use of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of migraine, wherein the medicament is to be administered nightly at an oral dose of 25-200 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, for at least thirty consecutive nights.

17. Use of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of migraine, wherein the medicament is to be administered at an oral dose of 25-200 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, every other night for at least ten consecutive nights.

18. Use of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of migraine, wherein the medicament is to be administered at an oral dose of 25-200 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof, every other night for at least thirty consecutive nights.

19. The use of claim 14, wherein the medicament is to be administered nightly at an oral dose of 25 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof.

20. The use of claim 14, wherein the medicament is to be administered nightly at an oral dose of 50 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof.

21. The use of claim 14, wherein the medicament is to be administered nightly at an oral dose of 75 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof.

22. The use of claim 14, wherein the medicament is to be administered nightly at an oral dose of 100 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof.

23. The use of claim 14, wherein the medicament is to be administered nightly at an oral dose of 150 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof.

24. The use of claim 14, wherein the medicament is to be administered nightly at an oral dose of 200 mg of 2,4,6-trifluoro-N-[6-(1-methyl-piperidin-4-ylcarbonyl)-pyridin-2-yl]-benzamide, or a pharmaceutically acceptable salt thereof.